Albert Assad

1.2k total citations
43 papers, 826 citations indexed

About

Albert Assad is a scholar working on Genetics, Radiology, Nuclear Medicine and Imaging and Hematology. According to data from OpenAlex, Albert Assad has authored 43 papers receiving a total of 826 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Genetics, 12 papers in Radiology, Nuclear Medicine and Imaging and 12 papers in Hematology. Recurrent topics in Albert Assad's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Albert Assad is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (14 papers), Chronic Myeloid Leukemia Treatments (9 papers) and Chronic Lymphocytic Leukemia Research (7 papers). Albert Assad collaborates with scholars based in United States, Australia and Spain. Albert Assad's co-authors include Bennett A. Landman, Yuankai Huo, Richard G. Abramson, Zhoubing Xu, Shunxing Bao, Robert F. Graziano, Peter Borchmann, Stephen M. Ansell, Thomas S. Lin and Steven Fischkoff and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Albert Assad

40 papers receiving 808 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Albert Assad United States 13 257 250 216 191 152 43 826
Dong Soon Lee South Korea 17 93 0.4× 267 1.1× 108 0.5× 153 0.8× 393 2.6× 59 1.0k
Edgar Gil Rizzatti Brazil 15 75 0.3× 254 1.0× 294 1.4× 285 1.5× 435 2.9× 42 1.0k
Jonathan L. Jesneck United States 18 278 1.1× 147 0.6× 67 0.3× 74 0.4× 718 4.7× 36 1.4k
Elodie Pronier United States 13 419 1.6× 194 0.8× 36 0.2× 136 0.7× 424 2.8× 17 1.2k
Sukjoong Oh South Korea 13 32 0.1× 252 1.0× 213 1.0× 107 0.6× 121 0.8× 52 783
Paulette Herlin France 17 205 0.8× 400 1.6× 143 0.7× 71 0.4× 282 1.9× 59 1.1k
Monica E. de Baca United States 13 117 0.5× 227 0.9× 243 1.1× 61 0.3× 124 0.8× 29 786
J. Andersen Denmark 16 161 0.6× 293 1.2× 103 0.5× 36 0.2× 225 1.5× 44 872
Wanming Hu China 17 98 0.4× 417 1.7× 82 0.4× 158 0.8× 215 1.4× 78 944
Indu Arun India 13 135 0.5× 233 0.9× 101 0.5× 57 0.3× 112 0.7× 51 597

Countries citing papers authored by Albert Assad

Since Specialization
Citations

This map shows the geographic impact of Albert Assad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Assad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Assad more than expected).

Fields of papers citing papers by Albert Assad

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Assad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Assad. The network helps show where Albert Assad may publish in the future.

Co-authorship network of co-authors of Albert Assad

This figure shows the co-authorship network connecting the top 25 collaborators of Albert Assad. A scholar is included among the top collaborators of Albert Assad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Assad. Albert Assad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Gerds, Aaron T., Niccolò Bartalucci, Albert Assad, & Abdulraheem Yacoub. (2022). Targeting the PI3K pathway in myeloproliferative neoplasms. Expert Review of Anticancer Therapy. 22(8). 835–843. 8 indexed citations
3.
Yacoub, Abdulraheem, Uma Borate, Raajit K. Rampal, et al.. (2022). MPN-075 Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Low Versus Higher Baseline Platelet Counts: A Subgroup Analysis of Data From a Phase 2 Study. Clinical Lymphoma Myeloma & Leukemia. 22. S324–S324. 2 indexed citations
4.
Yacoub, Abdulraheem, Susan Erickson‐Viitanen, Feng Zhou, & Albert Assad. (2021). A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus parsaclisib in patients with JAK- and PI3K-inhibitor treatment-naïve myelofibrosis.. Journal of Clinical Oncology. 39(15_suppl). TPS7058–TPS7058. 4 indexed citations
5.
Yacoub, Abdulraheem, Uma Borate, Raajit K. Rampal, et al.. (2021). MPN-127: Add-On Parsaclisib (a PI3K5 Inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study. Clinical Lymphoma Myeloma & Leukemia. 21. S354–S355. 6 indexed citations
6.
Tang, Yucheng, Yuankai Huo, Albert Assad, et al.. (2019). Improving splenomegaly segmentation by learning from heterogeneous multi-source labels. PubMed. 10949. 7–7. 14 indexed citations
7.
Huo, Yuankai, Richard G. Abramson, Richard Alan Peters, et al.. (2019). Acceleration of spleen segmentation with end-to-end deep learning method and automated pipeline. Computers in Biology and Medicine. 107. 109–117. 14 indexed citations
8.
Landman, Bennett A., Yuankai Huo, Shunxing Bao, et al.. (2018). Fully convolutional neural networks improve abdominal organ segmentation. PubMed. 10574. 100–100. 55 indexed citations
9.
Huo, Yuankai, Zhoubing Xu, Shunxing Bao, et al.. (2018). Splenomegaly segmentation using global convolutional kernels and conditional generative adversarial networks. PubMed. 10574. 8–8. 40 indexed citations
10.
Huo, Yuankai, Zhoubing Xu, Shunxing Bao, et al.. (2018). Adversarial synthesis learning enables segmentation without target modality ground truth. PubMed. 2018. 1217–1220. 83 indexed citations
11.
Bauer, Todd M., Manish R. Patel, Andres Forero‐Torres, et al.. (2018). A Phase Ib study of ruxolitinib + gemcitabine ± nab-paclitaxel in patients with advanced solid tumors. OncoTargets and Therapy. Volume 11. 2399–2407. 12 indexed citations
12.
Huo, Yuankai, Jiaqi Liu, Zhoubing Xu, et al.. (2017). Robust Multicontrast MRI Spleen Segmentation for Splenomegaly Using Multi-Atlas Segmentation. IEEE Transactions on Biomedical Engineering. 65(2). 336–343. 27 indexed citations
13.
Mascarenhas, John, Moshe Talpaz, Vikas Gupta, et al.. (2016). Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis. Haematologica. 102(2). 327–335. 86 indexed citations
14.
Fogelman, David R., Mark D. Kochenderfer, Gene Saylors, et al.. (2015). Phase II study of ruxolitinib with regorafenib for relapsed/refractory (r/r) metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 33(15_suppl). TPS3623–TPS3623.
15.
Assad, Albert & Olivier de Weck. (2014). Model of medical supply and astronaut health for long-duration human space flight. Acta Astronautica. 106. 47–62. 5 indexed citations
16.
Thertulien, Raymond, Arthur E. Frankel, Andrew M. Evens, et al.. (2009). Abstract #1227: A phase I, open-label, dose-escalation, multidose study of MDX-1401 (defucosylated human antiCD30 monoclonal antibody) in patients with CD30-positive refractory/relapsed Hodgkin\#8217;s lymphoma. Cancer Research. 69. 1227–1227. 10 indexed citations
17.
Ansell, Stephen M., Steven M. Horwitz, Andreas Engert, et al.. (2008). Increased doses of an anti-CD30 antibody, MDX-060, results in prolonged progression free survival in subjects with CD30 positive lymphoma.. Cancer Research. 68. 5525–5525. 2 indexed citations
18.
Assad, Albert & Joseph Caprioli. (1992). Digital image analysis of optic nerve head pallor as a diagnostic test for early glaucoma. Graefe s Archive for Clinical and Experimental Ophthalmology. 230(5). 432–436. 7 indexed citations
19.
Lea, Michael A., et al.. (1992). Inhibitory action of orotate, 2-thioorotate and isoorotate on nucleotide metabolism and nucleic acid synthesis in hepatoma cells. International Journal of Biochemistry. 24(9). 1453–1459. 6 indexed citations
20.
Lea, Michael A., et al.. (1990). Inhibitory effects of orotate on precursor incorporation into nucleic acids. Chemico-Biological Interactions. 75(1). 49–59. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Dong Soon Lee Breakdown of academic impact, for papers by Edgar Gil Rizzatti Breakdown of academic impact, for papers by Jonathan L. Jesneck Breakdown of academic impact, for papers by Elodie Pronier Breakdown of academic impact, for papers by Sukjoong Oh Breakdown of academic impact, for papers by Paulette Herlin Breakdown of academic impact, for papers by Monica E. de Baca Breakdown of academic impact, for papers by J. Andersen Breakdown of academic impact, for papers by Wanming Hu Breakdown of academic impact, for papers by Indu Arun
Rankless by CCL
2026